A “favorable” regulatory environment as FDA encourages making more drugs available nonprescription to help reduce health care costs will drive Rx-to-OTC switch growth over the next four years even without product categories including statins and asthma aids along for the ride, according to Kline Market Research.
Kline estimates OTC switch products will grow at a 5% compounded annual growth rate by 2019, according to its recent report,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?